骨科指南

订阅

MedSci主页 / 所有栏目 / 骨科指南

骨转换生化标志物临床应用指南

2021-11-10 中华医学会骨质疏松和骨矿盐疾病分会 中华骨质疏松和骨矿盐疾病杂志

骨质疏松

骨转换对于修复骨骼疲劳损伤和维持机体矿物质平衡至关重要,骨转换失衡是多种骨骼疾病的关键病理生理机制。

中文标题：

骨转换生化标志物临床应用指南

发布机构：

中华医学会骨质疏松和骨矿盐疾病分会

发布日期：

2021-11-10

简要介绍：

骨转换对于修复骨骼疲劳损伤和维持机体矿物质平衡至关重要,骨转换失衡是多种骨骼疾病的关键病理生理机制。骨转换生化标志物(bone turnover biomarkers,BTMs)是骨转换过程中产生的代谢产物或酶类，本指南陈述BTMs测量方法、正常值,及其在多种骨骼疾病的诊断与鉴别诊断、骨折风险预测、药物疗效评价等方面的应用。

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2093441, encodeId=3ad92093441ab, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512a2506321, createdName=颖子追, createdTime=Wed Oct 12 18:06:25 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207387, encodeId=3a48120e38728, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Mar 30 23:09:44 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193873, encodeId=af1911938e36d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28d5633954, createdName=ms8000001796725817, createdTime=Wed Feb 16 08:34:32 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181813, encodeId=5e71118181349, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib18tWbCzYcEibw6Ro7WIJDMuc2wJMj17F3Oj2d6Faia1LawEktGVQSxLd9FMILIQYwDLUK9u9WKDap5VY87R0GjeZ/0, createdBy=0acd1864050, createdName=6888, createdTime=Fri Jan 07 12:53:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071299, encodeId=d16a10e1299a4, content=收获得收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Thu Nov 18 08:53:23 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-10-12 颖子追

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2093441, encodeId=3ad92093441ab, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512a2506321, createdName=颖子追, createdTime=Wed Oct 12 18:06:25 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207387, encodeId=3a48120e38728, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Mar 30 23:09:44 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193873, encodeId=af1911938e36d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28d5633954, createdName=ms8000001796725817, createdTime=Wed Feb 16 08:34:32 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181813, encodeId=5e71118181349, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib18tWbCzYcEibw6Ro7WIJDMuc2wJMj17F3Oj2d6Faia1LawEktGVQSxLd9FMILIQYwDLUK9u9WKDap5VY87R0GjeZ/0, createdBy=0acd1864050, createdName=6888, createdTime=Fri Jan 07 12:53:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071299, encodeId=d16a10e1299a4, content=收获得收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Thu Nov 18 08:53:23 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-03-30 283488816

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2093441, encodeId=3ad92093441ab, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512a2506321, createdName=颖子追, createdTime=Wed Oct 12 18:06:25 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207387, encodeId=3a48120e38728, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Mar 30 23:09:44 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193873, encodeId=af1911938e36d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28d5633954, createdName=ms8000001796725817, createdTime=Wed Feb 16 08:34:32 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181813, encodeId=5e71118181349, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib18tWbCzYcEibw6Ro7WIJDMuc2wJMj17F3Oj2d6Faia1LawEktGVQSxLd9FMILIQYwDLUK9u9WKDap5VY87R0GjeZ/0, createdBy=0acd1864050, createdName=6888, createdTime=Fri Jan 07 12:53:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071299, encodeId=d16a10e1299a4, content=收获得收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Thu Nov 18 08:53:23 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-02-16 ms8000001796725817

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2093441, encodeId=3ad92093441ab, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512a2506321, createdName=颖子追, createdTime=Wed Oct 12 18:06:25 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207387, encodeId=3a48120e38728, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Mar 30 23:09:44 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193873, encodeId=af1911938e36d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28d5633954, createdName=ms8000001796725817, createdTime=Wed Feb 16 08:34:32 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181813, encodeId=5e71118181349, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib18tWbCzYcEibw6Ro7WIJDMuc2wJMj17F3Oj2d6Faia1LawEktGVQSxLd9FMILIQYwDLUK9u9WKDap5VY87R0GjeZ/0, createdBy=0acd1864050, createdName=6888, createdTime=Fri Jan 07 12:53:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071299, encodeId=d16a10e1299a4, content=收获得收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Thu Nov 18 08:53:23 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-01-07 6888

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2093441, encodeId=3ad92093441ab, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512a2506321, createdName=颖子追, createdTime=Wed Oct 12 18:06:25 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207387, encodeId=3a48120e38728, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Mar 30 23:09:44 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193873, encodeId=af1911938e36d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f28d5633954, createdName=ms8000001796725817, createdTime=Wed Feb 16 08:34:32 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181813, encodeId=5e71118181349, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib18tWbCzYcEibw6Ro7WIJDMuc2wJMj17F3Oj2d6Faia1LawEktGVQSxLd9FMILIQYwDLUK9u9WKDap5VY87R0GjeZ/0, createdBy=0acd1864050, createdName=6888, createdTime=Fri Jan 07 12:53:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071299, encodeId=d16a10e1299a4, content=收获得收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Thu Nov 18 08:53:23 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2021-11-18 liuyingying35

    收获得收益

    0

相关指南

症状性陈旧性胸腰椎骨质疏松性骨折手术治疗临床指南

中国骨科相关专家小组（统称） · 2020-07-30

骨质疏松的影像学与骨密度诊断专家共识

中华医学会放射学分会(CSR,chinese society of radiology) · 2020-08-10

围绝经期和绝经后妇女骨质疏松防治专家共识

中国老年学和老年医学学会(CAGG,China Association of Gerontology and Geriatrics) 骨质疏松分会 · 2020-08-10

2020 AACE/ACE临床实践指南：绝经后骨质疏松症的诊断和治疗

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2020-04-27

2020 专家共识建议：儿童继发性骨质疏松的诊断和治疗

国外风湿免疫科相关专家小组 · 2020-02-24

2020 EMAS/IGCS立场声明：妇科癌症后绝经期管理—聚焦围绝经期综合征和骨质疏松

欧洲女性与男性更年期协会(EMAS,European Menopause and Andropause Society) · 2020-02-11

拓展阅读

2009 COA骨质疏松骨折诊疗指南

中华医学会骨科学分会(COA,Chinese Orthopaedic Association) · 2009-10-01

2010NAMS 绝经后妇女骨质疏松症的管理

北美绝经学会(NAMS,The North American Menopause Society) · 2010-01-01

2010 NOF 临床医师指南：预防和治疗骨质疏松

美国国家骨质疏松基金会(NOF,National Osteoporosis Foundation) · 2010-01-01

2010AACE 绝经后骨质疏松诊治指南

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2010-01-01

2010RACGP 绝经后妇女和老年男性骨质疏松症的预防和治疗建议

澳大利亚皇家全科医师协会(RACGP,Royal Australian College of General Practitioners) · 2010-02-01

2010 ACR 糖皮质激素相关骨质疏松防治指南

美国风湿病学会(ACR,American College of Rheumatology) · 2010-11-01